Role of the Mmr Efflux Pump in Drug Resistance in Mycobacterium tuberculosis

ABSTRACT Efflux pumps are membrane proteins capable of actively transporting a broad range of substrates from the cytoplasm to the exterior of the cell. Increased efflux activity in response to drug treatment may be the first step in the development of bacterial drug resistance. Previous studies showed that the efflux pump Mmr was significantly overexpressed in strains exposed to isoniazid. In the work to be described, we constructed mutants lacking or overexpressing Mmr in order to clarify the role of this efflux pump in the development of resistance to isoniazid and other drugs in M. tuberculosis. The mmr knockout mutant showed an increased susceptibility to ethidium bromide, tetraphenylphosphonium, and cetyltrimethylammonium bromide (CTAB). Overexpression of mmr caused a decreased susceptibility to ethidium bromide, acriflavine, and safranin O that was obliterated in the presence of the efflux inhibitors verapamil and carbonyl cyanide m-chlorophenylhydrazone. Isoniazid susceptibility was not affected by the absence or overexpression of mmr. The fluorometric method allowed the detection of a decreased efflux of ethidium bromide in the knockout mutant, whereas the overexpressed strain showed increased efflux of this dye. This increased efflux activity was inhibited in the presence of efflux inhibitors. Under our experimental conditions, we have found that efflux pump Mmr is mainly involved in the susceptibility to quaternary compounds such as ethidium bromide and disinfectants such as CTAB. The contribution of this efflux pump to isoniazid resistance in Mycobacterium tuberculosis still needs to be further elucidated.

• Publication year

  2012

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2012-11-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.01482-12PMID 23165464PMCID PMC3553716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mycobacterium fortuitum.

  2022cited by this paper
• SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.

  2012cited by this paper
• Contribution of efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex.

  2012cited by this paper
• Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular drugs

  2012cited by this paper
• Efflux Pumps of Mycobacterium tuberculosis Play a Significant Role in Antituberculosis Activity of Potential Drug Candidates

  2012cited by this paper
• Contribution of Efflux to the Emergence of Isoniazid and Multidrug Resistance in Mycobacterium tuberculosis

  2012influential reference
• Identifying co-targets to fight drug resistance based on a random walk model

  2012cited by this paper
• Functional and Genetic Characterization of the Tap Efflux Pump in Mycobacterium bovis BCG

  2012cited by this paper
• Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.

  2011cited by this paper
• Inhibition of drug efflux in mycobacteria with phenothiazines and other putative efflux inhibitors.

  2011cited by this paper
• Biological activity of twenty-three hydantoin derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis NCTC 13349.

  2011cited by this paper
• Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis.

  2011cited by this paper
• Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability.

  2011cited by this paper
• Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance

  2011cited by this paper
• Microarray Analysis of Efflux Pump Genes in Multidrug-Resistant Mycobacterium tuberculosis During Stress Induced by Common Anti-Tuberculous Drugs

  2010cited by this paper
• Role of the Mycobacterium tuberculosis P55 Efflux Pump in Intrinsic Drug Resistance, Oxidative Stress Responses, and Growth

  2009cited by this paper
• Fluorometric determination of ethidium bromide efflux kinetics in Escherichia coli

  2009cited by this paper
• A Balancing Act: Efflux/Influx in Mycobacterial Drug Resistance

  2009cited by this paper
• Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis.

  2008cited by this paper
• Mycobacterial recombineering.

  2008cited by this paper
• Recombineering in Mycobacterium tuberculosis

  2007cited by this paper
• Role of mycobacterial efflux transporters in drug resistance: an unresolved question.

  2006cited by this paper
• "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries.

  2006cited by this paper
• Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria

  2006cited by this paper
• Efflux Pump-Mediated Intrinsic Drug Resistance in Mycobacterium smegmatis

  2004cited by this paper
• Resazurin Microtiter Assay Plate: Simple and Inexpensive Method for Detection of Drug Resistance in Mycobacterium tuberculosis

  2002cited by this paper
• Simple and Rapid Differentiation of Mycobacterium tuberculosis H37Ra from M. tuberculosis Clinical Isolates through Two Cytochemical Tests Using Neutral Red and Nile Blue Stains

  2002cited by this paper
• Molecular Cloning: A Laboratory Manual

  2001cited by this paper
• mmr, a Mycobacterium tuberculosis Gene Conferring Resistance to Small Cationic Dyes and Inhibitors

  1998cited by this paper
• Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.

  1998cited by this paper
• Construction of a family of Mycobacterium/Escherichia coli shuttle vectors derived from pAL5000 and pACYC184: their use for cloning an antibiotic-resistance gene from Mycobacterium fortuitum.

  1996cited by this paper
• New use of BCG for recombinant vaccines

  1991cited by this paper

• Efflux pump regulation and metabolic rewiring define the ceiling of efflux-mediated drug resistance in Mycobacteria

  2026cites this paper
• Unveiling the Mechanisms of Bacterial Resistance and Countermeasures

  2025cites this paper
• Drug Target Validation in Polyamine Metabolism and Drug Discovery Advancements to Combat Tuberculosis

  2025cites this paper
• Combating Multi-drug Resistant Mycobacterium Species by Efflux Pump Inhibitors: Contemporary Trends

  2025cites this paper
• Antimicrobial and Anti-Efflux Machinery of FDA-Approved Proton Pump Inhibitors and Vitamins Against Klebsiella pneumoniae and Pseudomonas aeruginosa

  2025cites this paper
• Mechanisms of Antibiotic Resistance and Novel Therapeutic Approaches for Mycobacterium tuberculosis: A Narrative Review With a Focus on Tuberculosis Mutations in Iran

  2025influential citation
• Determining the effect of a new truncated CecropinA-Magenin2 (CE-MA) hybrid peptide on the expression of multidrug-resistant (MDR) Mycobacterium tuberculosis efflux genes

  2025cites this paper
• Efflux systems driving resistance and virulence across biological domains

  2025cites this paper
• The efflux pumps Rv1877 and Rv0191 play differential roles in the protection of Mycobacterium tuberculosis against chemical stress

  2024cites this paper
• Insights to the Role of Phytoconstituents in Aiding Multi Drug Resistance - Tuberculosis Treatment Strategies.

  2024cites this paper
• Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c

  2023cites this paper
• Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors

  2023cites this paper
• GlnA3Mt is able to glutamylate spermine but it is not essential for the detoxification of spermine in Mycobacterium tuberculosis

  2023cites this paper
• Dual antituberculosis drugs-loaded gelatin hydrogel bioimplant for treating spinal tuberculosis.

  2023cites this paper
• The human proton pump inhibitors inhibit Mycobacterium tuberculosis rifampicin efflux and macrophage-induced rifampicin tolerance

  2023cites this paper
• The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic

  2022cites this paper
• Myoinositol and methyl stearate increases rifampicin susceptibility among drug‐resistant Mycobacterium tuberculosis expressing Rv1819c

  2022influential citation
• Structure-aided optimization of non-nucleoside M. tuberculosis thymidylate kinase inhibitors.

  2021cites this paper
• Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies

  2021cites this paper
• Critical discussion on drug efflux in Mycobacterium tuberculosis

  2021influential citation
• Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance.

  2021cites this paper
• In Vitro and In Silico Evaluations of Anti-Mycobacterium tuberculosis Activity of Benzohydrazones Compounds

  2021cites this paper
• Mycobacterial glycoproteins: Functions and their significance in tuberculosis

  2021cites this paper
• Measuring Efflux and Permeability in Mycobacteria.

  2021cites this paper
• Prevalence and Molecular Characteristics Based on Whole Genome Sequencing of Mycobacterium tuberculosis Resistant to Four Anti-Tuberculosis Drugs from Southern Xinjiang, China

  2021cites this paper
• Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis

  2020cites this paper
• Drugs against Mycobacterium tuberculosis

  2020cites this paper
• Drug Resistance Mechanisms In Tuberculosis | Encyclopedia

  2020cites this paper
• Characterization of the Mycobacterial MSMEG-3762/63 Efflux Pump in Mycobacterium smegmatis Drug Efflux

  2020cites this paper
• Are antibacterial effects of non-antibiotic drugs random or purposeful because of a common evolutionary origin of bacterial and mammalian targets?

  2020cites this paper
• Drug-Resistant Tuberculosis 2020: Where We Stand

  2020influential citation
• Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs

  2020cites this paper
• Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells

  2019cites this paper
• Genetics and roadblocks of drug resistant tuberculosis.

  2019cites this paper
• Efflux Pump Inhibitors, Alpha-Tocopherol and Aspirin: Role in Campylobacter jejuni and Campylobacter coli Fluoroquinolone Resistance

  2019cites this paper
• Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis.

  2019cites this paper
• Macrolides and Fluoroquinolones Resistance Mechanisms in Campylobacters and their Incidence in Egypt; a Review Article

  2019cites this paper
• Scrutinizing the drug resistance mechanism of multi- and extensively-drug resistant Mycobacterium tuberculosis: mutations versus efflux pumps

  2019cites this paper
• Mycobacterium tuberculosis Rv0191 is an efflux pump of major facilitator superfamily transporter regulated by Rv1353c.

  2019cites this paper
• The VirAB-VirSR-AnrAB Multicomponent System Is Involved in Resistance of Listeria monocytogenes EGD-e to Cephalosporins, Bacitracin, Nisin, Benzalkonium Chloride, and Ethidium Bromide

  2019cites this paper
• Verapamil as an Efflux Inhibitor Against Drug Resistant Mycobacterium Tuberculosis: A Review

  2019cites this paper
• Targeting redox heterogeneity to counteract drug tolerance in replicating Mycobacterium tuberculosis

  2019cites this paper
• Mechanistic investigation of resistance via drug-inactivating enzymes in Mycobacterium tuberculosis

  2018cites this paper
• Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis

  2018cites this paper
• Carvacrol activity & morphological changes in Mycobacterium tuberculosis.

  2018cites this paper
• Multi-drug efflux pumps : structure , function and regulation

  2018cites this paper
• Deregulation of Genes Associated with Alternate Drug Resistance Mechanisms in Mycobacterium tuberculosis

  2018cites this paper
• University of Groningen Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model Pieterman,

  2018cites this paper
• The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.

  2018cites this paper
• MdrL, a major facilitator superfamily efflux pump ofListeria monocytogenesinvolved in tolerance to benzalkonium chloride

  2018cites this paper
• Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence

  2018cites this paper
• Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria

  2018cites this paper
• Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors.

  2018cites this paper
• Deconvolution of Mycobacterium tuberculosis drug targets using high throughput screening approaches

  2018cites this paper
• Inhibiting Bacterial Drug Efflux Pumps via Phyto-Therapeutics to Combat Threatening Antimicrobial Resistance

  2018cites this paper
• The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase.

  2018cites this paper
• Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne’s model of dormancy

  2018cites this paper
• Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model

  2018cites this paper
• Multidrug efflux pumps: structure, function and regulation

  2018cites this paper
• Chapter 2 Bacterial Resistance to Hospital Disinfection

  2017cites this paper
• Efflux Attenuates the Antibacterial Activity of Q203 in Mycobacterium tuberculosis

  2017cites this paper
• Looking to nature for a new concept in antimicrobial treatments: isoflavonoids from Cytisus striatus as antibiotic adjuvants against MRSA

  2017cites this paper
• Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis.

  2017cites this paper
• Genomic Insight into Mechanisms of Reversion of Antibiotic Resistance in Multidrug Resistant Mycobacterium tuberculosis Induced by a Nanomolecular Iodine-Containing Complex FS-1

  2017cites this paper
• New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria

  2017cites this paper
• Active Efflux as a Mechanism of Resistance to Antimicrobial Drugs

  2017cites this paper
• Bacterial Resistance to Hospital Disinfection

  2017cites this paper
• Reversing antibacterial resistance of Staphylococcus aureus: the use of phytochemicals as antibiotic-adjuvants and resistance-modifying agents towards more effective therapies

  2017cites this paper
• Interplay between Mutations and Efflux in Drug Resistant Clinical Isolates of Mycobacterium tuberculosis

  2017cites this paper
• Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid

  2017cites this paper
• Antituberculosis drugs: reducing efflux=increasing activity.

  2017cites this paper
• Antimicrobial Resistance in Bacteria: An Overview of Mechanisms and Role of Drug Efflux Pumps

  2016cites this paper
• Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.

  2016cites this paper
• Drug-resistant tuberculosis viewed from bacterial and host genomes.

  2016cites this paper
• Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs.

  2016cites this paper
• An Experimental Model for the Rapid Screening of Compounds with Potential Use Against Mycobacteria

  2016cites this paper
• Combinatorial approaches with selected phytochemicals to increase antibiotic efficacy against Staphylococcus aureus biofilms

  2016cites this paper
• A study of the diagnosis, treatment and epidemiology of Mycobacterium abscessus in patients with cystic fibrosis

  2016cites this paper
• Biosynthesis and Roles of Virulence Conferring Cell Wall Associated Dimycocerosate Esters in Mycobacterium marinum

  2016cites this paper
• Biosynthesis and Roles of Virulence Conferring Cell Wall Associated Dimycocerosate Esters in Mycobacterium marinum

  2016cites this paper
• Efflux Pumps in Mycobacteria: Antimicrobial Resistance, Physiological Functions, and Role in Pathogenicity

  2016cites this paper
• Partial Depletion of Pth Increases Susceptibility to Macrolide Drug Treatment in M. Tuberculosis

  2016cites this paper
• Morphological changes and differentially expressed efflux pump genes in Mycobacterium tuberculosis exposed to a rifampicin and verapamil combination.

  2016cites this paper
• In Vitro Activity of Rifampicin and Verapamil Combination in Multidrug-Resistant Mycobacterium tuberculosis

  2015cites this paper
• Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy.

  2015cites this paper
• INSIGHTS INTO THIORIDAZINE FOR ITS ANTI-TUBERCULAR ACTIVITY FROM MOLECULAR DOCKING STUDIES Original Article

  2015cites this paper
• Cell membrane integrity and distinguishing between metabolically active and inactive cells as a means of improving viability PCR.

  2015cites this paper
• Overcoming drug resistance for tuberculosis.

  2015cites this paper
• Docking analysis insights quercetin can be a non-antibiotic adjuvant by inhibiting Mmr drug efflux pump in Mycobacterium sp. and its homologue EmrE in Escherichia coli

  2015cites this paper
• Measuring efflux and permeability in mycobacteria.

  2015cites this paper
• Mycobacterium tuberculosis Is Resistant to Isoniazid at a Slow Growth Rate by Single Nucleotide Polymorphisms in katG Codon Ser315

  2015cites this paper
• The Efflux Pump Inhibitor Timcodar Improves the Potency of Antimycobacterial Agents

  2014cites this paper
• Defining the role of efflux pump inhibitors on anti-TB drugs in Rifampicin resistant clinical Mycobacterium Tuberculosis isolates

  2014cites this paper
• Lipoamide channel-binding sulfonamides selectively inhibit mycobacterial lipoamide dehydrogenase.

  2013cites this paper